title: Pioglitazone increases adiponectin levels in nondiabetic patients with coronary artery disease.
abstract: OBJECTIVE
  Hypoadiponectinemia is associated with coronary artery disease (CAD). Pioglitazone has been shown to increase levels of adiponectin in diabetic patients. We sought to assess whether administration of pioglitazone to patients with CAD and without diabetes would affect plasma adiponectin levels and endothelial function.
  
  
  METHODS
  Seventeen patients with stable CAD and without evidence of diabetes were treated for 12 weeks with pioglitazone hydrochloride 30 mg daily. Adiponectin levels and endothelium-dependent flow-mediated vasodilation (ED-FMD) measurements were obtained pretreatment, posttreatment, and after a 12-week washout period.
  
  
  RESULTS
  Treatment with pioglitazone increased adiponectin levels from an average of 10.6 to 21.1 microg/ml (P=0.001) and improved ED-FMD from 4.45 to 8.43% (P=0.001).
  
  
  CONCLUSIONS
  Treatment with pioglitazone increased plasma adiponectin levels and improved ED-FMD in patients with stable CAD and no evidence of diabetes or insulin resistance.
authors.affiliation: Saint Vincent's Catholic Medical Center Manhattan, New York, NY 10011, USA.
authors.forename: Snehal R
authors.initials: SR
authors.lastname: Patel
authors.forename: Lynn M
authors.initials: LM
authors.lastname: Mailloux
authors.forename: John T
authors.initials: JT
authors.lastname: Coppola
authors.forename: Catalin
authors.initials: C
authors.lastname: Mindrescu
authors.forename: Cezar S
authors.initials: CS
authors.lastname: Staniloae
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001916:Brachial Artery / Q000187:drug effects / Q000502:physiology; D003324:Coronary Artery Disease / Q000503:physiopathology*; D018592:Cross-Over Studies; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000096:biosynthesis; D047495:PPAR gamma; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D014664:Vasodilation / Q000187:drug effects
chemical_list: D052242:Adiponectin; D007004:Hypoglycemic Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; D009569:Nitric Oxide; D000077205:Pioglitazone